Next Article in Journal
Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor
Next Article in Special Issue
The Regulatory Role of CTCF in IL6 Gene Transcription Assessed in Breast Cancer Cell Lines
Previous Article in Journal
Lebanese Medicinal Plants with Ophthalmic Properties
Previous Article in Special Issue
Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases

by
Alejandrina Hernández-López
1,2,
Alberto Olaya-Vargas
3,
Juan Carlos Bustamante-Ogando
4 and
Angélica Meneses-Acosta
1,*
1
Laboratorio 7 of Biotecnología Farmacéutica, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca 62210, Mexico
2
Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), Mexico City 03940, Mexico
3
Programa de Trasplante de Células Madre Hematopoyéticas y Terapia Celular, Instituto Nacional de Pediatría, Mexico City 04530, Mexico
4
Laboratorio de Investigación en Inmunodeficiencias y Departamento de Inmunología Clínica, Instituto Nacional de Pediatría, Mexico City 04530, Mexico
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(2), 156; https://doi.org/10.3390/ph18020156
Submission received: 6 October 2024 / Revised: 15 January 2025 / Accepted: 21 January 2025 / Published: 24 January 2025
(This article belongs to the Special Issue Tumor Immunopharmacology)

Abstract

CAR-T cell therapy has shown promising results in treating malignant hematologic diseases. The principle of this therapy is based on the use of genetically modified T lymphocytes to express a Chimeric Antigen Receptor (CAR) on their membrane that specifically recognizes an antigen predominantly expressed on target cells. The molecular design of the CAR, along with advancements in molecular techniques and the development of “omics”, has opened the possibility of discovering new therapeutic targets and thereby expanding the range of diseases treated with CAR-T cells beyond the use of anti-CD19 and anti-BCMA for hematologic cancer. This review summarizes the novel therapeutic targets that are currently used in clinical trials with CAR-T cell therapy on autoimmune diseases and other challenging conditions, such as cardiac fibrosis, and different infections. Additionally, challenges and novel opportunities are discussed for expanding clinical access to this innovative therapy.
Keywords: Chimeric Antigen Receptor; new CAR targets; CAR-T cell therapy Chimeric Antigen Receptor; new CAR targets; CAR-T cell therapy
Graphical Abstract

Share and Cite

MDPI and ACS Style

Hernández-López, A.; Olaya-Vargas, A.; Bustamante-Ogando, J.C.; Meneses-Acosta, A. Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases. Pharmaceuticals 2025, 18, 156. https://doi.org/10.3390/ph18020156

AMA Style

Hernández-López A, Olaya-Vargas A, Bustamante-Ogando JC, Meneses-Acosta A. Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases. Pharmaceuticals. 2025; 18(2):156. https://doi.org/10.3390/ph18020156

Chicago/Turabian Style

Hernández-López, Alejandrina, Alberto Olaya-Vargas, Juan Carlos Bustamante-Ogando, and Angélica Meneses-Acosta. 2025. "Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases" Pharmaceuticals 18, no. 2: 156. https://doi.org/10.3390/ph18020156

APA Style

Hernández-López, A., Olaya-Vargas, A., Bustamante-Ogando, J. C., & Meneses-Acosta, A. (2025). Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases. Pharmaceuticals, 18(2), 156. https://doi.org/10.3390/ph18020156

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop